A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC

Inclusion Criteria

• •1. age≥18
• •2. Non small cell lung cancer patients who have experienced pulmonary metastasis after PD-1 immunotherapy in the past
• •3. Voluntarily participate in this study and sign an informed consent form
• •4. The presence of evaluable size and number of pulmonary metastases on chest CT
• •5. There are indications for lung puncture biopsy
• •6. General physical condition (ECOG) 0-1
• •7. The laboratory test meets the following standards: white blood cell count\>3.5 × 109/L, absolute value of neutrophils\>1.8 × 109/L, platelet count ≥ 75 × 109/L, hemoglobin ≥ 100g/L; NR ≤ 1.5, and APTT ≤ 1.5 times the upper limit of normal value or partial prothrombin time (PT) ≤ 1.5 times the upper limit of normal value; Total bilirubin ≤ 1.25 times the upper limit of normal value; ALT and AST\<5 times the upper limit of normal values; 24-hour creatinine clearance rate\>50mL/min or blood creatinine\<1.5 times the upper limit of normal value.